Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin vs Ofloxacin + Metronidazole in Uncomplicated PID
NCT00683865Phase 3Completed
- Sponsor
- Bayer
- Start
- Apr 2003
- Primary completion
- Oct 2004
- Modality
- Orthosteric Ligands
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of moxifloxacin in pelvic inflammatory disease (PID) (2 arms), sponsored by Bayer. Primary endpoint: Clinical response at Test of Cure. Started Apr 2003; status: completed.
02
Drugs
moxifloxacin
03
Conditions
pelvic inflammatory disease (PID)
Beyond the preview
Go deeper on NCT00683865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00683865.